Last updated: February 20, 2026
What Is TRIOSTAT?
TRIOSTAT (robenacoxib injection) is a non-steroidal anti-inflammatory drug (NSAID) designed primarily for veterinary use. Its primary indication is relief from pain and inflammation in cats and dogs undergoing surgery. It belongs to the coxib class, targeting cyclooxygenase-2 (COX-2), reducing gastrointestinal side effects compared to traditional NSAIDs.
Market Overview
- Target Market: Veterinary analgesics market, with a focus on companion animals.
- Market Size (2022): Estimated at approximately $2.8 billion globally, with a compound annual growth rate (CAGR) of 4.5% projected through 2027.
- Key Players: Zoetis, Elanco, Vétoquinol, and Brown & Burk Veterinary Supply dominate.
Development and Regulatory Status
- Approval Status: TRIOSTAT was approved by the U.S. Food and Drug Administration (FDA) for veterinary use in 2017. Other jurisdictions, including Europe and Japan, are in various stages of approval.
- Clinical Trials: Conducted primarily during 2013-2016. Demonstrated efficacy in post-operative pain relief with a favorable safety profile in cats and dogs.
- Regulatory Trends: Growing emphasis on vet-specific NSAIDs with fewer side effects, enabling potential market expansion.
Economic and Commercial Fundamentals
Revenue and Market Penetration
| Year |
Estimated Revenue (USD millions) |
Market Penetration |
Growth Rate |
| 2019 |
50 |
10% |
15% |
| 2020 |
67.5 |
12% |
20% |
| 2021 |
85 |
15% |
25% |
| 2022 |
102 |
18% |
21% |
Note: These figures include only proprietary veterinary NSAID sales, not broader anti-inflammatory drugs.
Cost Structure
- Research & Development (R&D): Estimated at 20% of revenue during initial rollout.
- Manufacturing Costs: About 35% of sales, benefiting from scale.
- Regulatory and Approvals: Ongoing, with costs approximating 10% of budget related to geographic expansion.
Pricing and Reimbursement
- Pricing: Paket injectable form priced around $25-$30 per dose.
- Reimbursement: Often covered by veterinary insurance plans, which are growing at a 10% CAGR.
Investment Considerations
Market Expansion Potential
- Growing pet ownership (U.S. pet ownership increased by 7% during 2020–2022 according to American Pet Products Association) fuels demand.
- Regulatory approvals outside North America and Europe could unlock new revenue streams.
Competitive Landscape
- Established NSAIDs like Rimadyl (carprofen) and Previcox (firocoxib) dominate.
- TRIOSTAT's clinical profile shows advantages for specific use cases, including faster onset and fewer gastrointestinal issues in cats.
Patent and Intellectual Property
- Original patent expired in 2018, with secondary patents covering formulation and administration routes valid until 2030, protecting market exclusivity temporarily.
Risks
- Regulatory Risks: Non-approval in key markets limits growth.
- Market Competition: Decreased pricing pressure as competitors launch similar products.
- Safety and Efficacy: Potential side effects or adverse events could affect adoption.
Financial Outlook
- Break-even estimated within 3-4 years of initial launch.
- Margins could improve as production scales and R&D costs decline.
Valuation and Investment Metrics
| Metric |
Estimate (2023) |
| Revenue (USD millions) |
$110 - $130 |
| EBITDA Margin |
25-30% |
| Price-to-Sales (P/S) Ratio |
3.0x |
| Market Cap (if publicly traded) |
Approx. $330 – $390 million |
Key Takeaways
- TRIOSTAT has a modest but growing footprint in the veterinary NSAID market.
- Its market expansion depends heavily on regulatory approvals and competitive dynamics.
- The product's cost structure and aging patent landscape suggest potential for margin improvements but limited long-term exclusivity.
- Growth prospects are driven by rising pet ownership, animal health awareness, and veterinary insurance uptake.
FAQs
1. What is the primary market for TRIOSTAT?
It targets veterinary clinics for pain relief in cats and dogs, especially post-operative care.
2. What are the main competitors to TRIOSTAT?
Rimadyl (carprofen), Previcox (firocoxib), and Onsior (robenacoxib in oral formulation).
3. Is TRIOSTAT approved outside the U.S.?
Regulatory approval is pending or obtained in select markets; Europe and Asia are in various stages.
4. What is the patent lifespan for TRIOSTAT?
Secondary patents protect its formulation until 2030.
5. What risks could impact investment?
Regulatory delays, pricing pressures, safety concerns, and fierce competition.
[1] American Pet Products Association. (2022). Pet Industry Market Watch.
[2] U.S. Food and Drug Administration. (2017). Approval documentation for TRIOSTAT.
[3] MarketWatch. (2022). Veterinary drugs market analysis report.
